The cancer treatment developer has raised $94m in equity and grant funding, with Pfizer, Celgene and Baxter among its shareholders.

Hatteras Venture Partners could receive up to $20m from Malin for the $150m fund it is raising, having also secured GlaxoSmithKline and LabCorp as limited partners.

General electric-backed genomics tool developer RainDance Technologies has called off its initial public offering after raising more than $100m in equity.

Merck has led a funding round for Navigating Cancer, which supports cancer patients by keeping them actively informed about their care.

Corporate-backed weight loss programme provider Finc has received $5.3m in debt and an undisclosed amount in equity funding.

OSU has spun out NeurXstem to further develop and commercialise research that is able to create a human brain in a dish.

Google's corporate venturing unit led a round that boosted Zephyr Health's overall funding to more than $33m.

Buffalo spinout Cytocybernetics hopes its technology will help stop drug candidates failing clinical trials for causing heart attacks.